Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 9, 2015, Pages 1663-1678

  Koehne, Guenther ^a,b   Hasan, Aisha ^a   Doubrovina, Ekaterina ^a   Prockop, Susan ^a   Tyler, Eleanor ^a,b   Wasilewski, Gloria ^a   O'Reilly, Richard J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adoptive immunotherapy; Epitope specific and HLA restricted T cell responses; Overlapping pentadecapeptides; Persistent cytomegalovirus (CMV) infection

Indexed keywords

CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PENTADECAPEPTIDE; POLYPEPTIDE; UNCLASSIFIED DRUG; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PEPTIDE; PHOSPHOPROTEIN;

ADOPTIVE TRANSFER; ADULT; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPITOPE MAPPING; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; LYMPHOCYTE TRANSFER; MIDDLE AGED; PERSISTENT VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; T CELL DEPLETION; VIRAL CLEARANCE; VIREMIA; AGED; ALLOGRAFT; CHILD; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DONOR; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; MALE; PATHOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

AGED; ALLOGRAFTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; PEPTIDES; PHOSPHOPROTEINS; T-LYMPHOCYTES; TISSUE DONORS; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 84938988442     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.015     Document Type: Article

References (64)

1. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T cell immunity. Blood 2003, 101:407-414.
2. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
3. Zaia J.A., Gallez-Hawkins G.M., Tegtmeier B.R., et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997, 176:782-785.
4. Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant 1998, 21(Suppl 2):S72-S74.
5. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
6. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
7. Quinnan G.V., Kirmani N., Rook A.H., et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982, 307:7-13.
8. Ohnishi M., Sakurai T., Heike Y., et al. Evaluation of cytomegalovirus-specific T cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T cell epitope. Br J Haematol 2005, 131:472-479.
9. Moins-Teisserenc H., Busson M., Scieux C., et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008, 198:818-826.
10. Luo X.H., Huang X.J., Liu K.Y., et al. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:994-1004.
11. Avetisyan G., Larsson K., Aschan J., et al. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 38:687-692.
12. Pourgheysari B., Piper K.P., McLarnon A., et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009, 43:853-861.
13. Widmann T., Sester U., Gartner B.C., et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008, 3:e3634.
14. Lacey S.F., Diamond D.J., Zaia J.A. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004, 10:433-447.
15. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
16. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
17. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T cell lines. Lancet 2003, 362:1375-1377.
18. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
19. Micklethwaite K., Hansen A., Foster A., et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:707-714.
20. Micklethwaite K.P., Clancy L., Sandher U., et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008, 112:3974-3981.
21. Trivedi D., Williams R.Y., O'Reilly R.J., Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005, 105:2793-2801.
22. Hasan A.N., Kollen W.J., Trivedi D., et al. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol 2009, 183:2837-2850.
23. Koehne G., Smith K.M., Ferguson T.L., et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002, 99:1730-1740.
24. Doubrovina E., Carpenter T., Pankov D., et al. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 2012, 120:1633-1646.
25. Waldrop S.L., Pitcher C.J., Peterson D.M., et al. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997, 99:1739-1750.
26. Wei S., Charmley P., Robinson M.A., Concannon P. The extent of the human germline T cell receptor V beta gene segment repertoire. Immunogenetics 1994, 40:27-36.
27. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
28. Landry M.L., Ferguson D., Stevens-Ayers T., et al. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence. J Clin Microbiol 1996, 34:1337-1339.
29. Ehrnst A., Barkholt L., Brattstrom C., et al. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993, 39:118-124.
30. Kearns A.M., Turner A.J., Eltringham G.J., Freeman R. Rapid detection and quantification of CMV DNA in urine using LightCycler-based real-time PCR. J Clin Virol 2002, 24:131-134.
31. Mhiri L., Kaabi B., Houimel M., et al. Comparison of pp65 antigenemia, quantitative PCR and DNA hybrid capture for detection of cytomegalovirus in transplant recipients and AIDS patients. J Virol Methods 2007, 143:23-28.
32. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 1996, 70:7569-7579.
33. Boppana S.B., Britt W.J. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 1996, 222:293-296.
34. Khan N., Best D., Bruton R., et al. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007, 178:4455-4465.
35. Ameres S., Besold K., Plachter B., Moosmann A. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. J Immunol 2014, 192:5894-5905.
36. Lin A., Xu H., Yan W. Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol 2007, 4:91-98.
37. Yanada M., Yamamoto K., Emi N., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 32:801-807.
38. Nakamura R., Cortez K., Solomon S., et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:235-242.
39. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
40. Doubrovina E., Oflaz-Sozmen B., Kernan N., et al. Adoptive transfer of EBV-specific T cells for treatment of primary and rituxan-resistant EBV lymphomas following allogeneic stem cell transplants (HSCT): clinical, viral and immunologic correlates. BBSMT 2010, 16(Supplement 2):S220.
41. Doubrovina E., Oflaz-Sozmen B., Prockop S.E., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656.
42. Heslop H.E., Ng C.Y., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
43. Haque T., Wilkie G.M., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360:436-442.
44. Feuchtinger T., Opherk K., Bethge W.A., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
45. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
46. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T cell-depleted stem cell transplantation. Blood 2000, 95:2240-2245.
47. Gottschalk S., Ng C.Y., Perez M., et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97:835-843.
48. Zaia J.A., Gallez-Hawkins G., Li X., et al. Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J Virol 2001, 75:2472-2474.
49. Jones T.R., Hanson L.K., Sun L., et al. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol 1995, 69:4830-4841.
50. Ahn K., Angulo A., Ghazal P., et al. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A 1996, 93:10990-10995.
51. Kim S., Lee S., Shin J., et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol 2011, 12:984-991.
52. Bao L., Cowan M.J., Dunham K., et al. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother 2012, 35:293-298.
53. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
54. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
55. Papadopoulou A., Gerdemann U., Katari U.L., et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014, 6:242ra283.
56. Heslop H.E. Pharmacotherapy versus T lymphocytes for CMV. Blood 2013, 121:3544-3545.
57. Kern F., Bunde T., Faulhaber N., et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002, 185:1709-1716.
58. Lacey S.F., Villacres M.C., La Rosa C., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003, 64:440-452.
59. Blyth E., Clancy L., Simms R., et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121:3745-3758.
60. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202:379-386.
61. Schmitt A., Tonn T., Busch D.H., et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011, 51:591-599.
62. Uhlin M., Gertow J., Uzunel M., et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55:1064-1073.
63. Giest S., Grace S., Senegaglia A.C., et al. Cytomegalovirus-specific CD8(+) T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. Br J Haematol 2010, 148:311-322.
64. Prockop S.E., Hasan A., Koehne G., et al. Third-party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant. [ASH Meeting Abstracts]. Blood 2014, 124:184. abstract.